Agenus (NASDAQ: AGEN) is one of 174 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Agenus to similar businesses based on the strength of its risk, dividends, profitability, valuation, earnings, institutional ownership and analyst recommendations.
This table compares Agenus and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Agenus and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Agenus||$22.57 million||-$126.99 million||-3.03|
|Agenus Competitors||$219.16 million||-$39.69 million||-70.01|
Agenus’ peers have higher revenue and earnings than Agenus. Agenus is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Agenus has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Agenus’ peers have a beta of 1.66, suggesting that their average stock price is 66% more volatile than the S&P 500.
This is a breakdown of current recommendations for Agenus and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Agenus currently has a consensus price target of $6.33, suggesting a potential upside of 78.91%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.55%. Given Agenus’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Agenus is more favorable than its peers.
Insider & Institutional Ownership
37.9% of Agenus shares are held by institutional investors. Comparatively, 48.4% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 7.6% of Agenus shares are held by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Agenus peers beat Agenus on 7 of the 13 factors compared.
Agenus Company Profile
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company’s discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company’s vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.